Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).
Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, González-García JJ, Cepeda C, Hervás R, Paño JR, Gaya F, Carcas A, Montes ML, Costa JR, Peña JM. Arribas JR, et al. Among authors: miralles p. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4. J Acquir Immune Defic Syndr. 2005. PMID: 16249701 Clinical Trial.
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, Dronda F, Antela A, Sanz J, Navas E, Miralles P, Berenguer J, Pérez S, Zapata A, González-García JJ, Peña JM, Vázquez JJ, Arribas JR. Montes ML, et al. Among authors: miralles p. J Antimicrob Chemother. 2005 May;55(5):800-4. doi: 10.1093/jac/dki063. Epub 2005 Mar 10. J Antimicrob Chemother. 2005. PMID: 15761071 Clinical Trial.
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, Rubio R, González-García J, Miralles P, Pérez-Elías MJ, Ocampo A, Hernando A, Estrada V, Clotet B, Podzamczer D, Arribas JR. Pulido F, et al. Among authors: miralles p. Antivir Ther. 2009;14(2):195-201. doi: 10.1177/135965350901400210. Antivir Ther. 2009. PMID: 19430094
Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy.
Berenguer J, Miralles P, Ribera JM, Rubio R, Valencia E, Mahillo B, Pintado V, Palacios R, Montes ML, Téllez MJ, La Cruz J, Torre-Cisneros J, Rodríguez-Arrondo F, Sepúlveda MA, Gutiérrez F, Peralta G, Boix V. Berenguer J, et al. Among authors: miralles p. J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):422-8. J Acquir Immune Defic Syndr. 2008. PMID: 18434957
Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.
Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Berenguer J, et al. Among authors: miralles p. Clin Infect Dis. 2012 Sep;55(5):728-36. doi: 10.1093/cid/cis500. Epub 2012 May 18. Clin Infect Dis. 2012. PMID: 22610932
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.
Brochado Ó, Martínez I, Berenguer J, Medrano L, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Navarro J, Guardiola JM, Fernández-Rodríguez A, Resino S; GESIDA Study Group. Brochado Ó, et al. J Biomed Sci. 2021 Mar 30;28(1):23. doi: 10.1186/s12929-021-00718-6. J Biomed Sci. 2021. PMID: 33785040 Free PMC article.
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients.
Carrero A, Berenguer J, Hontañón V, Guardiola JM, Navarro J, von Wichmann MA, Téllez MJ, Quereda C, Santos I, Sanz J, Galindo MJ, Hernández-Quero J, Jiménez-Sousa MA, Pérez-Latorre L, Bellón JM, Resino S, Esteban H, Martínez E, González-García J; Grupo de Estudio del Sida (GESIDA) 3603B Study Group. Carrero A, et al. Clin Infect Dis. 2021 Oct 5;73(7):e2026-e2033. doi: 10.1093/cid/ciaa1396. Clin Infect Dis. 2021. PMID: 32930720
240 results